{"preliminary_commentary":{"by_channel":{"youtube":3,"x_thread":2,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"CEVOLUTION","nct_id":"NCT07555938","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=cevolution-nct07555938. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"CEVOLUTION","arms":[{"description":"Cevostamab will be administered intravenously on a 21-day cycle in cycle 1 and on a 28-day cycle from cycle 2 onwards.\n\nPomalidomide will be administered orally (PO) on a 28-day cycle from cycle 2 onwards.\n\nDexamethasone will be administered as a premedication prior to cevostamab.","label":"Cevostamab + Pomalidomide + Dexamethasone","type":"EXPERIMENTAL"},{"description":"Participants will receive investigator's choice of one SOC regimen.","label":"Standard of Care (SOC)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2033-01-31","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":380,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Cevostamab","otherNames":[],"type":"DRUG"},{"name":"Pomalidomide","otherNames":[],"type":"DRUG"},{"name":"Dexamethasone","otherNames":[],"type":"DRUG"},{"name":"Daratumumab","otherNames":[],"type":"DRUG"},{"name":"Elotuzumab","otherNames":[],"type":"DRUG"},{"name":"Carfilzomib","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-13","lead_sponsor":"Hoffmann-La Roche","official_title":"A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Patients With Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-10-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Minimal Residual Disease (MRD)-Negative Complete Response (CR) Rate","timeFrame":"Up to 1 year after the last participant is randomized"},{"measure":"Progression-Free Survival (PFS)","timeFrame":"Up to 5 years after the last participant is randomized"}],"references":[],"start_date":{"date":"2026-06-23","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT07555938"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/cevolution-nct07555938"}